Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2025-01-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2024-0886.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849760948002226176 |
|---|---|
| author | Hiroaki Kanzaki Yujin Hoshida |
| author_facet | Hiroaki Kanzaki Yujin Hoshida |
| author_sort | Hiroaki Kanzaki |
| collection | DOAJ |
| format | Article |
| id | doaj-art-0401d0da033b4a80ac67975e7a61adf8 |
| institution | DOAJ |
| issn | 2287-2728 2287-285X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj-art-0401d0da033b4a80ac67975e7a61adf82025-08-20T03:06:10ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2025-01-01311e121e12210.3350/cmh.2024.08862064Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”Hiroaki Kanzaki0Yujin Hoshida1 Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USAhttp://e-cmh.org/upload/pdf/cmh-2024-0886.pdfhepatocellular carcinomaimmunotherapypredictive biomarkertumor immune microenvironment |
| spellingShingle | Hiroaki Kanzaki Yujin Hoshida Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” Clinical and Molecular Hepatology hepatocellular carcinoma immunotherapy predictive biomarker tumor immune microenvironment |
| title | Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_full | Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_fullStr | Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_full_unstemmed | Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_short | Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_sort | reply to correspondence on genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma insights from the imbrave150 trial |
| topic | hepatocellular carcinoma immunotherapy predictive biomarker tumor immune microenvironment |
| url | http://e-cmh.org/upload/pdf/cmh-2024-0886.pdf |
| work_keys_str_mv | AT hiroakikanzaki replytocorrespondenceongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial AT yujinhoshida replytocorrespondenceongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial |